急性早幼粒细胞白血病:HARMONY项目的长期结局
基于HARMONY平台分析1999至2022年诊断的1438例新发急性早幼粒细胞白血病患者,比较全反式维甲酸联合三氧化二砷(ATRA-ATO)与以伊达比星为基础的化疗(AIDA样化疗)的长期结局,并重新定义预后因素。ATRA-ATO方案7年总生存91%、无事件生存89%、复发3%,均优于AIDA样化疗;早期死亡发生率为5.9%,与年龄增长和高Sanz风险评分独立相关。
要点
- ATRA-ATO方案7年总生存91% vs AIDA样化疗81%,无事件生存89% vs 71%,复发3% vs 13%。
- 早期死亡发生于1438例中85例(5.9%),中位时间为诊断后9天。
- 早期死亡与年龄增长(OR 1.06)和高Sanz风险评分(OR 4.65)独立相关。
核心结论
- 研究证实ATRA-ATO方案在急性早幼粒细胞白血病患者中优于ATRA联合化疗。
- 降低早期死亡风险仍是未满足的医疗需求,尤其是在老年和高危急性早幼粒细胞白血病患者中。
研究设计与样本
- 利用HARMONY平台分析1999年至2022年间诊断的1438例新发急性早幼粒细胞白血病患者。
- 患者数据来自2项国际多中心试验(GIMEMA-APL0406和NCRI-AML17)和4个欧洲登记处(HOVON、AMLSG、瑞典AML登记处和SAL)。
- 队列包括721例男性和717例女性,中位年龄50.5岁(范围16-94岁)。
- 1309例开始治疗的患者中,562例接受ATRA-ATO,747例接受以伊达比星为基础的化疗(AIDA样化疗)。
- 中位随访5.5年(四分位距3.2-7.5年)。
主要发现
- 早期死亡发生于1438例中85例(5.9%),中位时间为急性早幼粒细胞白血病诊断后9天。
- 早期死亡与年龄增长独立相关(OR 1.06;95%CI 1.04-1.08),与高Sanz风险评分独立相关(OR 4.65;95%CI 2.55-8.51)。
- ATRA-ATO方案7年总生存率为91%,AIDA样化疗为81%(HR 2.14;95%CI 1.51-3.05)。
- ATRA-ATO方案7年无事件生存率为89%,AIDA样化疗为71%(HR 2.72;95%CI 2.01-3.69)。
- ATRA-ATO方案复发率为3%,AIDA样化疗为13%(HR 4.19;95%CI 2.38-7.39;所有结局P < .001)。
关键数值与推荐
- ATRA-ATO方案7年总生存91% vs AIDA样化疗81%(HR 2.14;95%CI 1.51-3.05)。
- ATRA-ATO方案7年无事件生存89% vs AIDA样化疗71%(HR 2.72;95%CI 2.01-3.69)。
- ATRA-ATO方案复发率3% vs AIDA样化疗13%(HR 4.19;95%CI 2.38-7.39;所有结局P < .001)。
- 早期死亡与年龄增长相关(OR 1.06;95%CI 1.04-1.08),与高Sanz风险评分相关(OR 4.65;95%CI 2.55-8.51)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Treatment outcomes for acute promyelocytic leukemia (APL) have improved with the widespread use of targeted therapy with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). Our study aimed to validate these data in a large patient cohort, and to redefine prognostic factors. Leveraging the HARMONY Platform, we analyzed 1438 newly diagnosed patients with APL, diagnosed between 1999 and 2022. Patient data derived from the 2 international multicenter Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA)-APL0406 and National Cancer Research Institute (NCRI)-AML17 trials and 4 European registries: the Haemato Oncology Foundation for Adults in the Netherlands, Belgium and Luxembourg (HOVON), AML Study Group (AMLSG), Swedish AML Registry, and Study Alliance Leukemia (SAL). The study cohort included 721 males and 717 females, with a median age of 50.5 years (range, 16-94 years). Of 1309 patients starting therapy, 562 received ATRA-ATO, and 747 idarubicin-based chemotherapy (AIDA-like CHT). Early death (ED) occurred in 85 of 1438 patients (5.9%) at a median of 9 days after APL diagnosis and was independently associated with increasing age and high Sanz risk score (odds ratio [OR], 1.06; 95% confidence interval [CI], 1.04-1.08; and OR, 4.65; 95% CI, 2.55-8.51, respectively). The median follow-up was 5.5 years (interquartile range, 3.2-7.5 years). ATRA-ATO regimen was associated with the best outcome, reaching 91% 7-year overall survival (vs 81% for AIDA-like CHT; hazard ratio [HR], 2.14; 95% CI, 1.51-3.05), 89% event-free survival (vs 71% for AIDA-like CHT; HR, 2.72; 95% CI, 2.01-3.69), and 3% relapse (vs 13% for AIDA-like CHT; HR, 4.19; 95% CI, 2.38-7.39; P < .001 for all outcomes). The survival advantage of ATRA/ATO was independent of patients' age, Sanz risk score, and treatment scenario. Our study confirms the superiority of ATRA-ATO over ATRA-chemotherapy in patients with APL. Reducing the risk of ED still represents an unmet medical need, in particular in older patients and in high-risk APL.
引用
- Voso MT, Guarnera L, Lehmann S, et al. Acute promyelocytic leukemia: long-term outcomes from the HARMONY project. Blood. 2025. PMID: 39504485. doi:10.1182/blood.2024026186
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。